Intellia Therapeutics presented positive clinical data at a conference, showing deep reductions in kallikrein levels in patients with hereditary angioedema who received lonvo-z. Among the patients who received a 50 mg dose, 97% were attack-free and long-term prophylaxis-free, with 75% remaining so for at least seven months. The drug also demonstrated a well-tolerated safety profile for up to three years. The Phase 3 HAELO clinical trial is ongoing, with results expected by mid-2026, offering hope for a one-time treatment for HAE patients. The data presented at the conference support the potential of lonvo-z to revolutionize HAE treatment.

Read more at GlobeNewswire: Intellia Therapeutics Presents Positive Pooled Phase 1/2